ESPE Yearbook of Paediatric Endocrinology

Brief Summary: This large cohort study of 27,997 individuals aged 3-18 years with obesity in Sweden examined the effect of obesity severity and obesity treatment on growth. Prepubertal individuals with class II (more severe) obesity were had higher height-for age and growth velocity than children with class I obesity. After onset of puberty, these individuals and especially boys, showed slower height velocity and a blunted growth spurt. The final height z score in this study p...

Brief Summary: This review evaluated the impact of gene mutations in the leptin-melanocortin pathway on short- and long-term outcomes after bariatric surgery, which is still the most effective treatment for severe obesity. This topic is of high clinical relevance, since such mutations play an important role in hunger regulation and energy homeostasis [1, 2] and may therefore confer weight regain after bariatric surgery [3]. To date there have been few publications, often with ...

Brief Summary: For both clinicians and patients, it is of great interest to have easily-applicable predictors to forecast weight reductions achievable by lifestyle intervention (LI). This study identified 3 distinct clusters of responses to paediatric outpatient LI. Up to 2 years after LI initiation, responses ranged from ‘pronounced BMIz loss’ (in 19% of patients; median delta-BMIz: -0.61 (IQR: -0.76 to -0.49) to ‘moderate BMIz loss’ (in 45%; -0.23 (-0.33 ...

Brief Summary: This phase 2, open-label, multicenter trial examined the efficacy of setmelanotide, a melanocortin-4 receptor agonist, in patients aged 6 to 40 years with obesity due to hypothalamic injury. Setmelanotide reduced body mass index (BMI) and hunger levels in most participants; 89% achieved a reduction in BMI of at least 5% after 16 weeks. These results indicate that setmelanotide is a promising treatment for hypothalamic obesity.This phase 2 ...

Brief Summary: The study investigated how tirzepatide, a dual GIPR/GLP-1R agonist, modulates adipocyte nutrient metabolism by long-acting activation of the GIP receptor. It shows that tirzepatide enhances insulin signaling, glucose uptake, and lipid metabolism in adipocytes, contributing to improved metabolic outcomes in both fasted and fed states.Tirzepatide has recently been shown to have superior efficacy in reducing HbA1c, body weight, and serum trig...